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Genetic Risk Factors for Type 2 Diabetes:
A Trans-Regulatory Genetic Architecture?
Steven C. Elbein,1,7,8 Eric R. Gamazon,2,7 Swapan K. Das,1 Neda Rasouli,3,4 Philip A. Kern,5,6
and Nancy J. Cox2,*
To date, 68 loci have been associated with type 2 diabetes (T2D) or glucose homeostasis traits. We report here the results of experiments
aimed at functionally characterizing the SNPs replicated for T2D and glucose traits. We sought to determine whether these loci were
associated with transcript levels in adipose, muscle, liver, lymphocytes, and pancreatic b-cells. We found an excess of trans, rather
than cis, associations among these SNPs in comparison to what was expected in adipose and muscle. Among transcripts differentially
expressed (FDR < 0.05) between muscle or adipose cells of insulin-sensitive individuals and those of insulin-resistant individuals
(matched on BMI), trans-regulated transcripts, in contrast to the cis-regulated ones, were enriched. The paucity of cis associations
with transcripts was confirmed in a study of liver transcriptome and was further supported by an analysis of the most detailed transcrip-
tome map of pancreatic b-cells. Relative to location- and allele-frequency-matched random SNPs, both the 68 loci and top T2D-associ-
ated SNPs from two large-scale genome-wide studies were enriched for trans eQTLs in adipose and muscle but not in lymphocytes. Our
study suggests that T2D SNPs have broad-reaching and tissue-specific effects that often extend beyond local transcripts and raises the
question of whether patterns of cis or trans transcript regulation are a key feature of the architecture of complex traits.Introduction
To date, at least 68 regions have shown replicated associa-
tion with type 2 diabetes (T2D; MIM 125853), fasting or
post-challenge glucose levels, or insulin sensitivity.1–3
These variants are all common SNPs; with just a few
exceptions, the disease-associated SNPs are themselves
noncoding—they reside in either intronic or intergenic
regions—and are not in linkage disequilibriumwith known
nonsynonymous SNPs. Hence, few of the T2D- and
glucose-homeostasis-associated SNPs are likely to alter
protein function; rather, they are expected to alter gene
regulation and/or splicing.4,5 Because many of the T2D-
and glucose-homeostasis-associated SNPs are also associ-
ated with measures of insulin secretion (such measures
are often surrogate, as in HOMA-B or insulin response to
oral glucose),6 most have been thought to act primarily to
alter pancreatic b-cell function.7 Nonetheless, the specific
transcripts reported to be implicated by GWAS findings
are often at a considerable distance from the disease-associ-
ated SNP. In rare cases do functional data implicate any
particular gene or transcript in the disease association.
Furthermore, many of the transcripts near T2D-associated
SNPs are widely expressed, including in the diabetes-
relevant tissues liver, adipose, and muscle. Thus, a much
broader impact on T2D susceptibility is plausible, and
the actual molecular and physiological explanations for
these well-replicated associations remain uncertain.1Section on Endocrinology and Metabolism, Department of Internal Medicin
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has recently elucidated and expanded on GWAS find-
ings.8,9 For example, a recent eQTL study in liver showed
that some implicated transcripts for type 1 diabetes (MIM
222100) were probably incorrect.8 A recent study of celiac
disease (MIM 212750)10 reported that 52% of disease-asso-
ciated SNPs were also associated with cis-regulated eQTLs
in blood cells. Nicolae et al.11 reported that SNPs associated
with traits from the Wellcome Trust Case Control Consor-
tium were more likely to be eQTLs (e.g., particularly cis
eQTLs in Crohn disease [MIM 266600]) in transformed
lymphocytes, supporting the use of surrogate tissues to
identify functional transcripts. Nica et al.12 reported
similar findings. These studies did not specifically address
the question of whether the SNPs reproducibly associated
with T2D and related traits are more likely to be eQTLs
than randomly selected SNPs of similar frequency.11
Hence, functional data explaining the association of
SNPs with T2D and glucose homeostasis are lacking.
Furthermore, the tacit assumption in suggesting that these
disease-associated SNPs act through specific transcripts
near T2D- and glucose-homeostasis2,3,13-associated SNPs
is without supportive data.
Although our results provide some support for the
regulation of transcripts near GWAS SNPs by cis-acting
eQTLs and more generally support a role of these SNPs in
tissues other than pancreatic b-cells, our analyses suggest
a much broader role for GWAS SNPs in controlling distale, Wake Forest School of Medicine, Winston-Salem, NC 27157; 2Section of
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transcripts than has been appreciated. We found that repli-
cated T2D- and glucose-homeostasis-associated SNPs were
enriched for trans eQTLs for transcripts differentially ex-
pressed between insulin-sensitive and insulin-resistant
individuals. In contrast to recent studies using transformed
lymphocytes,11,12 we further found that trans eQTLs (and
not cis eQTLs) in adipose andmuscle were enriched among
the top associations from recently published T2D GWAS
studies. Hence, eQTL mapping in tissues relevant to glu-
cose homeostasis promises to provide insights into the
mechanisms driving T2D susceptibility.Methods
Ethics Statement
All study participants provided written, informed consent under
protocols originally approved by the University of Arkansas for
Medical Sciences Institutional Review Board.
Human Subjects and Tissues: Adipose and Muscle
Details of the study for transcript levels with insulin sensitivity in
adipose and muscle tissue were previously described.14 In brief,
individuals were chosen from previous studies for availability of
both adipose and muscle biopsy samples and insulin sensitivity
(SI) calculated from the insulin-modified, intravenous glucose-
tolerance test. Participants were of age 20–55 years, their body
mass index (BMI) was between 19 kg/m2 and 42 kg/m2, and all
biopsies were obtained while participants were in the fasting state.
Adipose biopsies were obtained under local anesthesia from
abdominal subcutaneous fat by either needle biopsy (34 individ-
uals) or incision (28 individuals), rinsed in saline, and frozen in
liquid nitrogen. Muscle samples were obtained from the vastus
lateralis by Bergstrom needle biopsy under local anesthesia and
frozen in liquid nitrogen. Samples included in the study were
obtained from 62 of 184 total study participants (136 European
American, 48 African American) who were at the tails of the
distribution of insulin sensitivity adjusted for age, gender, and
natural logarithmof BMI for each ethnic group separately. Individ-
uals in each tail were well matched for age, gender, BMI, and
percent fat but were significantly different for SI (p < 10
5). The
numbers of adipose and muscle samples were evenly divided
between the extremes of the insulin-sensitivity distribution (i.e.,
31 samples were insulin sensitive, and 31 were insulin resistant).
RNA was extracted, and labeled cRNA was prepared by linear
amplification of the poly(A)þ RNA population within the total-
RNA sample. Total RNA (1 mg) was reverse transcribed after being
primed with a DNA oligonucleotide containing the T7 RNA poly-
merase promoter 50 to a d(T)24 sequence. After second-strand
cDNA synthesis and purification of double-stranded cDNA,
in vitro transcription was performed with T7 RNA polymerase.
We fragmented 1 mg of purified cRNA to uniform size and hybrid-
ized to Human Whole Genome 4344k arrays (Agilent Technolo-
gies, Santa Clara, CA, USA) at 37C for 18 hr, after which arrays
were washed and scanned with a G2565 Microarray Scanner
(Agilent Technologies).
Arrays were processed and background corrected with default
settings of the Agilent Feature Extraction software v.9.5.3.1 (Agi-
lent Technologies), and raw intensity data from each gene were
quantile normalized to the 75th percentile intensity of each array.
Only transcripts with values greater than background intensity inThe Americanall samples were included for analysis in the current study. For
comparison of insulin-sensitive and insulin-resistant individuals,
array intensities were processed with the nonparametric Wilcoxan
statistic on normalized data in Statistical Analysis for Microarray
(SAM) software15. We calculated false-discovery rates (q value)
on the basis of >400 permutations.Liver Samples and Expression Arrays
Details of the study on the identification, replication, and
functional fine mapping of eQTLs in primary human liver tissue
and demographic information on the samples were previously
described.16 In brief, liver was obtained from normal, nondiseased
specimens of 220 individuals from deceased unrelated donors
of self-reported European and African descent. The liver tissue
samples were derived from donor livers not used for organ trans-
plants and from tissues that remained after a partial graft into
a smaller patient (e.g., a pediatric patient). RNA was extracted by
homogenization in TRIzol reagent followed by QIAGEN RNeasy
column (QIAGEN, Germantown, MD, USA). From total RNA,
labeled cRNA was prepared, hybridized to Agilent 4344 arrays,
washed, and scanned as described above.Genome-wide Association
For the adipose and muscle sample, all 62 individuals underwent
genotyping with the Illumina 1M platform. Genotyping was per-
formed at the Pharmacogenomics Laboratory of the Central
Arkansas Veterans Healthcare System according to standard Illu-
mina protocols. The full marker set included 1,124,117 SNPs and
had a genotyping rate of 0.999 and 8039 markers excluded for
deviation from Hardy-Weinberg equilibrium (Fisher’s exact test,
p% 0.001). Of the 62 individuals, 45 were reported to be female,
which was confirmed prior to genotyping via X and Y chromo-
some markers. Using Illumina X chromosome genotype data to
assign gender based on heterozygosity rate, we determined three
samples to be ambiguous.
DNA was extracted from liver samples, and genotyping was
performed on the Illumina human 610 quad beadchip (Illumina,
San Diego, CA, USA). Of the 620,901 SNPs in the full set, we
excluded 8,300 markers for deviation from Hardy-Weinberg equi-
librium (Fisher’s exact test, p% 0.001). We excluded an additional
29,705 SNPs for more than 10% missing genotypes.
We used the probe genomic coordinates to map each probe by
using Agilent probe annotation to NCBI Entrez database, build
36. Probes that could not be annotated to a RefSeq gene and Entrez
identifier were excluded from further analysis. To avoid spurious
eQTLs resulting from SNPs residing under probe sequences,17 we
flagged all probes that mapped to a variant in dbSNP (v129),18
although 60-mers used in Agilent arrays are less likely to give
spurious results than shorter probes.Ancestry Estimation
We used the HapMap CEU, YRI, and ASN populations as refer-
ence panels and performed a principal-component analysis
(PCA) of race on each study sample by using GWAS data.
PCA was conducted with ‘‘smartpca’’ as implemented in the
EIGENSTRAT program.19 For the 62 samples comprising 40 Euro-
pean American and 22 African American samples, the samples
clustered as expected from self-identified ethnicity: European
American samples clustered tightly with HapMap CEU individ-
uals and African American samples showed the presence of Euro-
pean admixture.Journal of Human Genetics 91, 466–477, September 7, 2012 467
Transcript Selection
We identified 68 well-replicated SNPs that were associated with
T2D, fasting glucose levels,1–3,20–22 insulin sensitivity,23 and post-
challenge glucose levels3 and that were in the public domain. For
each region, we used SCAN24 to identify transcripts that overlap-
ped the regions near the implicated SNPs (defined as the 1 Mb
region centered at the SNP) and that contained variants in linkage
disequilibrium with those SNPs (r2 > 0.3), resulting in 183 identi-
fied transcripts (Table S1 in the Supplemental Data available with
this article online).Transcript Association with Insulin Sensitivity
For transcripts near replicated SNPs associated with T2D andmeta-
bolic traits, we report t-test-based associations with insulin sensi-
tivity. We examined all data (European American and African
American) together, and given the primary association in Euro-
pean-ancestry populations, we tested European American samples
separately. We report the n-fold difference, single-point p value,
and Q value for each comparison.Where multiple probes were ob-
served, we provide the best result and indicate alternative probes.eQTL Mapping
We imputed untyped variation by using MACH25 to increase the
number of SNPs for eQTL mapping. We used probe-level analysis
of expression with two linear models to map expression-quantita-
tive traits. First, we constructed a linear model involving the
combined study samples:
P ¼ mþ Rþ e
where P is the normalized probe-level expression value, m is the ex-
pected value of the probe expression intensity, R is the genetic
ancestry covariate, and e is the residual error. A second model is
a population-specific linear model (in the European Americans).
According to the ancestry estimation we conducted with Eigen-
strat,19 there was no need to include any of the population-specific
eigenvectors as covariates in the second model.
For each model, we performed eQTL mapping by testing each
marker for the additive effect of allele dosage on covariate-adjusted
normalized probe-level expression intensity. Cis-regulatory ele-
ments were defined to be SNPs within 500 kb of the probe because
a recent study has shown that most fall within that genomic
segment upstream or downstream from the target gene.26 Trans-
acting elements were defined as those more than 500 kb away
from the probe on the same chromosome or as those on a different
chromosome. We tested the evidence for each eQTL association
under each of the twomodels: that in which the combined sample
was adjusted for ancestry and the population-specific linear model
for European Americans.
The presence of unmeasured or hidden factors such as batch
effects, technical factors, and other global confounders might
reduce the power to detect eQTLs. We thus utilized the probabi-
listic estimation of expression residuals (PEER) framework,27
which is related to surrogate variable analysis and infers hidden
determinants of expression variation. We utilized the residual
data set of expression values generated after regressing out the
learned factors. The pairwise correlation between the normalized
expression levels and the resulting residuals in adipose or muscle
tissue for the probes for the transcripts included in our analysis
had a mean of 0.99 and standard deviation of 0.01.
We used PLINK28 to calculate theMAF for each SNP in each pop-
ulation separately and in the combined sample set to identify rare468 The American Journal of Human Genetics 91, 466–477, SeptembSNPs (MAF< 5%), which were excluded from analysis on the basis
of insufficient power to detect significant transcript associations.
To test whether the replicated T2D and glucose-homeostasis-
associated SNPs, as well as the top signals in two independent
large-scale GWASs (WTCCC29 and a GWAS of T2D in Mexican
Americans from Starr County, TX30), were enriched for eQTLs,
in each case we generated 1,000 randomly selected sets of SNPs
of the same size and matching MAF and location (with respect
to the nearest gene) as those of the test set, as previously
described.11 We empirically generated the null distribution by
counting the number of expression-associated SNPs (at p < 103)
in each random set for each tissue evaluated separately. We also
evaluated enrichment at p < 104 for the SNP-transcript associa-
tion in order to test the robustness of an enrichment result to
the choice of p value threshold. We estimated the enrichment p
value by comparing the observed expression-associated SNP count
to the null distribution. Using a similar simulation procedure, we
conducted a cis eQTL (within 500 kb) enrichment analysis for each
tissue included in the study. We performed an extended cis eQTL
enrichment analysis for SNPs within 4 Mb of a gene to test the
robustness of our observation on the paucity of cis-regulatory
signals. To investigate whether the observed enrichment in repro-
ducibly associated T2D- and glucose-homeostasis-associated SNPs
was driven by LD, we performed a simulation analysis with a strin-
gent r2 threshold of less than 0.30, as previously described.11Results
We sought functional data for each of the 68 regions impli-
cated by replicated association with T2D and glucose-
homeostasis traits (fasting or postchallenge glucose levels
or insulin sensitivity) (See Table 1). We considered recent
data that most cis-acting variants are within genes or are
close to transcription start or stop sites.26 Thus, we chose
all transcripts that overlap the regions near the implicated
SNPs (defined as the 1 Mb region centered at the SNP) and
that contained variants in linkage disequilibrium with
those SNPs (r2 > 0.3). We identified 183 such transcripts,
of which nearly 60%were expressed in at least one of three
tissues important to T2D pathogenesis: liver, subcutaneous
adipose, and muscle.
Figure 1 is a schematic diagram of our approach. We
report the results of three major analyses:er 71. Association analyses between the full set of SNPs
(nearly 1 million) and a limited number of tran-
scripts (n ¼ 183) were aimed at identifying eQTLs
for transcripts near T2D and glucose-trait-associated
SNPs (Figure 1A). We also considered the subset of
the 183 transcripts that were differentially expressed
between insulin-sensitive and insulin-resistant indi-
viduals.
2. Association analyses between a limited number
of SNPs (n ¼ 68) and the full set of transcripts
(n ¼ 13,024 in muscle and n ¼ 15,507 in adipose
tissue) to functionally characterize the T2D and
glucose-trait-associated SNPs as eQTLs (Figure 1B).
We also characterized target transcripts that were, 2012
Table 1. SNPs Replicated for Type 2 Diabetes and Glucose-
Homeostasis Traits
SNP Chromosome Position Alleles Gene MIM ID
rs10010131 4 6,343,816 A/G WFS1 606201
rs10423928 19 50,874,144 A/T GIPR 137241
rs10440833 6 20,796,100 A/T CDKAL1 611259
rs10811661 9 22,124,094 C/T
rs10830963 11 92,348,358 C/G MTNR1B 600804
rs10885122 10 113,032,083 G/T
rs10923931 1 120,319,482 G/T NOTCH2 600275
rs10965250 9 22,123,284 A/G
rs11071657 15 60,221,254 A/G
rs1111875 10 94,452,862 A/G
rs11558471 8 118,254,914 A/G SLC30A8 611145
rs11605924 11 45,829,667 A/C CRY2 603732
rs11634397 15 78,219,277 A/G
rs11642841 16 52,402,988 A/C FTO 610966
rs11708067 3 124,548,468 A/G ADCY5 600293
rs11899863 2 43,472,323 C/T THADA 611800
rs11920090 3 172,200,215 A/T SLC2A2 138160
rs12243326 10 114,778,805 C/T TCF7L2 602228
rs1260326 2 27,584,444 C/T GCKR 600842
rs12779790 10 12,368,016 A/G
rs13081389 3 12,264,800 A/G
rs13266634 8 118,253,964 C/T SLC30A8 611145
rs13292136 9 81,141,948 C/T
rs1387153 11 92,313,476 C/T
rs1470579 3 187,011,774 A/C IGF2BP2 608289
rs1531343 12 64,461,161 C/G
rs1552224 11 72,110,746 G/T ARAP1 606646
rs163184 11 2,803,645 G/T KCNQ1 607542
rs17271305 15 60,120,272 A/G VPS13C 608879
rs174550 11 61,328,054 C/T FADS1 606148
rs1801214 4 6,353,923 C/T WFS1 606201
rs1801282 3 12,368,125 C/G PPARG 601487
rs2191349 7 15,030,834 G/T
rs2237892 11 2,796,327 C/T KCNQ1 607542
rs231362 11 2,648,047 C/T KCNQ1 607542
rs243021 2 60,438,323 C/T
rs2877716 3 124,577,141 C/T ADCY5 600293
rs2943641 2 226,801,989 C/T
rs340874 1 212,225,879 A/G
rs35767 12 101,399,699 C/T
rs3802177 8 118,254,206 C/T SLC30A8 611145
Table 1. Continued
SNP Chromosome Position Alleles Gene MIM ID
rs4430796 17 33,172,153 A/G HNF1B 189907
rs4457053 5 76,460,705 A/G
rs4506565 10 114,746,031 A/T TCF7L2 602228
rs4607103 3 64,686,944 C/T
rs4607517 7 44,202,193 A/G
rs4760790 12 69,921,061 A/G
rs5015480 10 94,455,539 C/T
rs5215 11 17,365,206 C/T KCNJ11 600937
rs560887 2 169,471,394 A/G G6PC2 608058
rs5945326 X
rs6795735 3 64,680,405 C/T
rs7034200 9 4,279,050 A/C GLIS3 610192
rs757210 17 33,170,628 A/G HNF1B 189907
rs7578326 2 226,728,897 A/G
rs7578597 2 43,586,327 C/T THADA 611800
rs7754840 6 20,769,229 C/G CDKAL1 611259
rs780094 2 27,594,741 A/G GCKR 600842
rs7903146 10 114,748,339 C/T TCF7L2 602228
rs7944584 11 47,292,896 A/T MADD 603584
rs7957197 12 119,945,069 A/T OASL 603281
rs7961581 12 69,949,369 C/T
rs8042680 15 89,322,341 A/C PRC1 603484
rs849134 7 28,162,747 A/G JAZF1 606246
rs864745 7 28,147,081 A/G JAZF1 606246
rs896854 8 96,029,687 A/G TP53INP1 606185
rs972283 7 130,117,394 A/G
rs9939609 16 52,378,028 A/T FTO 610966
The American Joudifferentially expressed between insulin-sensitive
and insulin-resistant individuals.
3. Tissue-level enrichment analyses for expression-
associated SNPs—first, among the T2D- and
glucose-trait-associated SNPs, then among the top
associations from T2D GWASs—for adipose and
muscle transcripts associated with insulin sensitivity
and for transcripts in additional tissues (Figure 1C).eQTLs for Transcripts near T2D and Glucose-Trait
Associated SNPs
On the basis of the hypothesis that SNPs identified in
GWASs are acting locally to alter transcript expression,
we searched for cis eQTLs controlling these 183 transcripts
(Figure 1A).
For simplicity, we refer to T2D- and glucose-trait-associ-
ated SNPs as ‘‘T2D/GT SNPs.’’ We refer to the transcriptsrnal of Human Genetics 91, 466–477, September 7, 2012 469
Figure 1. A Schematic Diagram of the
Analyses
(A) We conducted association analyses
between the full set of SNPs (nearly 1
million) and a limited number of tran-
scripts (n ¼ 183) to identify eQTLs for
transcripts near T2D- and glucose-trait-
associated SNPs. We also considered the
subset of the 183 transcripts that were
differentially expressed between insulin-
sensitive and insulin-resistant individuals.
(B) We conducted association analyses
between a limited number of SNPs (n ¼
68) and the full set of transcripts (n ¼
13,024 in muscle and n ¼ 15,507 in
adipose) to functionally characterize the
T2D- and glucose-trait-associated SNPs as
eQTLs. We also characterized target tran-
scripts that were differentially expressed
between insulin-sensitive and insulin-
resistant individuals.
(C) We performed tissue-level enrich-
ment analyses for expression-associated
SNPs—first, among the T2D- and glucose-trait-associated SNPs, then among the top associations from T2D GWASs—for adipose and
muscle transcripts associated with insulin sensitivity and for transcripts in additional tissues.that overlap the 1Mb regions centered at the T2D/GT SNPs
and that contain variants in LD (r2 > 0.3) with those SNPs
as transcripts ‘‘near the T2D/GT SNPs.’’
To test each expressed transcript near the T2D/GT SNPs
in adipose for control by eQTLs, we conducted separate
analyses for trans-acting and cis-acting (under 500 kb)
eQTLs. Given the number of adipose-expressed (n ¼ 106)
transcripts near T2D/GT SNPs and the nearly 1 million
SNPs tested, we used p < 5 3 1010 (based on Bonferroni
adjustment) to search for trans eQTLs. Notably, we identi-
fied genome-wide-significant trans eQTLs for nine of
the transcripts located near T2D/GT SNPs, including
MAPK8IP1 (MIM 604641) (e.g., rs2696490, p ¼ 7.18 3
1024), TCF7L2 (MIM 602228) (e.g., rs11198893, p ¼
2.19 3 1011), SEC61A2 (e.g., rs12935562, p ¼ 2.12 3
1010), and PPP2R2C (MIM 605997) (rs3765618, p ¼
4.78 3 1010). In adipose, we identified cis eQTLs for five
of the 106 expressed transcripts after correction based on
the actual number of cis tests for adipose-expressed tran-
scripts near T2D/GT SNPs (p < 106). Cis eQTLs were
found for two transcripts in the GCKR region on chromo-
some 2: KRTCAP3 (rs1647266, p ¼ 1.71 3 107) and
SUPT7L (MIM 612762) (rs2178197, p ¼ 7.10 3 1010).
Additional cis eQTLs were for VPS33B (MIM 608552)
(rs7403304, p ¼ 9.86 3 107)); SYN2 (MIM 600755)
(rs13089415, p ¼ 3.8 3 108); and OASL (MIM 603281)
(rs959398, p ¼ 1.94 3 108). Interestingly, these cis-regu-
lated transcripts near T2D/GT SNPs were also trans targets
for other genome-wide-significant eQTLs (such transcripts
included KRTCAP3 [rs35980734, p ¼ 2.9 3 1010]) or were
implicated by strong trans associations (that were just short
of having Bonferroni significance) (such transcripts in-
cluded OASL [rs6854530, p ¼ 6.55 3 1010]). These results
in adipose are summarized in Table S2.
Similarly, we evaluated each muscle-expressed transcript
near the T2D/GT SNPs for eQTL regulation; again, we470 The American Journal of Human Genetics 91, 466–477, Septembtested for trans-acting and cis-acting (under 500 kb) eQTLs
separately. Given the number of transcripts that were near
T2D/GT SNPs and were expressed in muscle (n ¼ 97) and
the nearly 1 million SNPs tested, we used p < 5 3 1010
(based on Bonferroni adjustment) to search for trans-
acting eQTLs. We detected several such trans eQTLs for
three transcripts, namely MAPK8IP1 (MIM 604641) (e.g.,
rs2696490, p ¼ 3.5 3 1017), C11orf9 (MIM 608329)
(e.g., rs2278210, p ¼ 5.4 3 1012), and GTF3C2 (MIM
604883) (e.g., rs7733988, p ¼ 1.12 3 1010). Of note,
rs2696490 was a trans eQTL for MAPK8IP1 in both adipose
and muscle. Under the same criteria in muscle to define
a cis eQTL (based on the actual number of cis tests, p <
106), no cis eQTLs were detected for transcripts near
T2D/GT SNPs. These results in muscle are summarized in
Table S3.
In general, transcripts near T2D/GT SNPs were not under
cis eQTL control in either adipose or muscle. Interestingly,
we identified several more that were under trans eQTL
regulation (by using a stringent Bonferroni threshold).
Insulin Sensitivity and Transcripts near T2D and
Glucose-Trait-Associated SNPs
A recent analysis argued that eQTLs near a SNP associated
with T2D or glucose homeostasis are not necessarily func-
tionally related to disease.12 Because our sample was drawn
from individuals matched on body mass index and discor-
dant for insulin sensitivity (SI), we asked whether each
transcript near T2D/GT SNPs was also differentially ex-
pressed in insulin-sensitive versus insulin-resistant indi-
viduals and whether such differentially expressed tran-
scripts were controlled by eQTLs (Figure 1A). We used an
FDR31 approach for multiple testing and defined a tran-
script as ‘‘differentially expressed between insulin-sensitive
and insulin-resistant individuals’’ or as ‘‘associated with
insulin sensitivity’’ if the transcript satisfied FDR < 0.05.er 7, 2012
Near the T2D/GT SNP rs10010131 in WFS1 (MIM
606201), adipose transcript PPP2R2C, a trans target for
the eQTL rs3765618 (p ¼ 4.78 3 1010), was increased
with insulin resistance (1.36-fold change). Among the
transcripts near T2D/GT SNPs, no cis-associated transcripts
in adipose were associated with insulin sensitivity. In
muscle, among the transcripts near T2D/GT SNPs, no
target transcripts (either cis- or trans- associated with an
eQTL) were found to be associated with insulin sensitivity.
At a loose threshold (p < 1 3 108) for a candidate regu-
latory SNP’s association with transcript levels for tran-
scripts near the T2D/GT SNPs, we found that no additional
adipose transcript and only one muscle transcript, FADS1
(MIM 606148) (trans associated with rs17004857, p ¼
5.5 3 109), differed between insulin-sensitive and
insulin-resistant individuals. Furthermore, transcript levels
(for transcripts near T2D/GT SNPs) associated with candi-
date cis-regulatory SNPs (at a less stringent threshold, p <
104) for transcripts including SUPT7L, JAZF1 (MIM
606246), SYN2, KRTCAP3, and NOSTRIN (MIM 607496)
did not differ between insulin-sensitive and insulin-
resistant subjects, despite suggestions that SYN2 and
JAZF1 are the transcripts accounting for SNP associations
with T2D.
More generally, transcripts (in either adipose or muscle)
near T2D/GT SNPs were not enriched for transcripts associ-
ated with insulin sensitivity (Fisher’s exact test, p > 0.05).
Taken together, these data suggest that cis eQTLs for
transcripts near T2D/GT SNPs are relatively unusual
(indeed, several more transcripts near T2D/GT SNPs were
found to be associated with trans-acting eQTLs) and largely
tissue specific and that even in adipose and muscle the
transcripts are not strongly associated with insulin sensi-
tivity.
T2D- and Glucose-Trait-Associated SNPs as cis and
trans eQTLs for Transcripts Associated with Insulin
Sensitivity
Given the small number of cis eQTLs identified for tran-
scripts near the 68 T2D and glucose-homeostasis-associ-
ated regions according to the 500 kb criteria, we asked
whether T2D/GT SNPs were acting either more distally
on the same chromosome or to control transcripts on
other chromosomes (Figure 1B).
For each of the T2D/GT SNPs, we tested for association
between the SNP and transcript levels in adipose and
muscle (evaluated separately). After Bonferroni correction
based on the 68 T2D/GT SNPs and the 15,507 tested
expressed transcripts in adipose (p < 4.7 3 108), we
observed that replicated T2D SNP rs13081389 was a cis
eQTL (p ¼ 3.8 3 108) for SYN2. In muscle, given the
13,024 expressed transcripts tested, no T2D/GT SNPs met
genome-wide significance after a stringent Bonferroni
correction (p< 5.63 108). However, we observed a signif-
icant enrichment for low p values among the trans associ-
ations, suggesting that the corresponding SNPs are master
regulators of gene expression.The AmericanWe then used p < 103 to filter the results of association
testing between the T2D/GT SNPs and transcripts in
muscle and adipose (evaluated separately). We used this
loose threshold to identify a comprehensive list of tran-
scripts that, although only nominally associated with es-
tablished T2D/GT SNPs, were significantly differentially
expressed, at a stringent threshold (FDR < 0.05), between
insulin-sensitive and insulin-resistant individuals. Further-
more, we sought to determine whether transcripts nomi-
nally associated with T2D/GT SNPs were more likely to
be differentially expressed (FDR < 0.05) between insulin-
sensitive and insulin-resistant individuals than transcripts
associated (at the same nominal level of association p <
103) with a random set of allele-frequency-matched
SNPs. Finally, we sought to test the hypothesis that tran-
scripts associated with T2D/GT SNPs, in trans versus in
cis, were differentially expressed between insulin-sensitive
and insulin-resistant individuals. We tested other p value
thresholds for SNP-transcript association (p < 0.01, 0.05,
and 0.10) and found that at the threshold p < 103 (but
not at less-stringent p value thresholds), the T2D/GT
SNPs were more significantly associated than expected
with transcripts differentially expressed between insulin-
sensitive and insulin-resistant individuals.
We considered transcripts associated with T2D/GT SNPs
in muscle. We identified a single cis eQTL rs1635852, a
proxy (r2 ¼ 0.965) for the T2D-associated SNP rs864745,
that was intronic in JAZF1 and associated with the expres-
sion of the gene (p¼ 1.083 105). However, JAZF1was not
significantly associated (p > 0.05) with insulin sensitivity.
Notably, this same SNP was associated with several tran-
scripts in trans, including PRPF19 (MIM 608330) (p ¼
2.4 3 105), a gene involved in transcriptional regulation
in the development of the endocrine pancreas.32 Such
widespread effects on transcription may be mediated
through the actions of JAZF1, reported to be a tran-
scriptional repressor. Transcript levels of MRPS6 (MIM
611973) and CHMP1A (MIM 164010) (both of which
were trans associated with the same T2D SNP rs7034200,
p¼ 8.033 105 and p¼ 3.713 105, respectively) differed
significantly between insulin-sensitive and insulin-resis-
tant individuals. Table S4 provides the full list of muscle
transcripts that were associated with established T2D/GT
SNPs and were differentially expressed between insulin-
sensitive and insulin-resistant individuals.
For transcripts associated with T2D/GT SNPs in adipose,
the results were similar. The SNP rs13081389 was signifi-
cantly (Bonferroni) associated (p ¼ 3.8 3 108) with SYN2
transcript levels 66 kb away; however, SYN2was not associ-
ated with insulin sensitivity. Similarly, SNP rs4712523 was
nominally associated (p¼ 2.453 104, in cis) withCDKAL1
(MIM 611259); transcript levels, however, did not differ
between insulin-sensitive and insulin-resistant individuals.
No additional cis-associated transcripts were found. In
contrast, we found 20 transcripts that were trans associated
with T2D/GT SNPs and significantly associated with
insulin sensitivity. Table S5 contains the full list of adiposeJournal of Human Genetics 91, 466–477, September 7, 2012 471
transcripts that were associated with replicated T2D/GT
SNPs and were differentially expressed between insulin-
sensitive and insulin-resistant individuals.
Taken together, these initial findings raised the hypoth-
esis that replicated T2D/GT SNPs as putative eQTLs
functioned in trans to alter the expression of transcripts
that differed between insulin-sensitive and insulin-resis-
tant individuals. Because these findings appeared to
hold when we considered transcripts associated with
T2D/GT SNPs at various thresholds (p < 103 and p <
104)—although, as expected given our sample size,
using a more stringent definition reduced their absolute
numbers—we sought to assess the significance of this over-
lap between transcripts associated with established T2D/
GT SNPs and transcripts differentially expressed between
insulin-sensitive and insulin-resistant individuals.
Tissue-Specific Enrichment of eQTLs for Transcripts
Associated with Insulin Sensitivity among T2D- and
Glucose-Homeostasis-Associated SNPs
It is possible that the observed number of transcripts that
were (nominally) trans associated with T2D/GT SNPs and
significantly associated with insulin sensitivity could
simply reflect the large numbers of tests at this level;
many of these are expected to have false-positive findings.
Thus, we devised a simulation procedure to evaluate this
possibility. We asked whether established T2D/GT SNPs
showed more associations as putative trans-acting eQTLs
with transcripts differentially expressed between insulin-
sensitive and insulin-resistant individuals than expected
by chance (Figure 1C). Using 1,000 sets of randomly gener-
ated SNPs whose MAF and location with respect to genes
matched those of the T2D/GT SNPs (see Methods), we
found that established T2D/GT SNPs were significantly
more likely to be trans associated with differentially
expressed transcripts than frequency-matched SNPs in
adipose (enrichment p ¼ 0.048). In contrast, no such
enrichment was found for cis-associated transcripts
(whether associated with insulin sensitivity or not). Con-
sistent with this adipose finding, in muscle, we saw that
two established T2D/GT SNPs, rs2881654 and rs7041847,
were trans associated with differentially expressed tran-
scripts (GGT6 [MIM 612341] and HDAC10 [MIM 608544]
were associated with the first SNP andMRPS6 and CHMP1A
were associated with the second), whereas no cis-acting
eQTLs were identified among the T2D/GT SNPs for differ-
entially expressed transcripts; however, the small number
of SNPs trans associated with differentially expressed tran-
scripts in muscle for both the empirically generated null
sets and the set of replicated T2D/GT SNPs precludes
enrichment analyses.
Because we identified cis eQTLs for only a small minority
of transcripts near T2D/GT SNPs in adipose andmuscle, we
proceeded to test whether each of the T2D/GT SNPs was
associated with target transcripts in a more extended cis
region up to 4Mb. At the threshold p< 0.001 for SNP asso-
ciation with gene expression, we observed no enrichment472 The American Journal of Human Genetics 91, 466–477, Septembwhen we used the extended definition of cis (enrichment
p ¼ 0.366 and p ¼ 0.160 in adipose and muscle, respec-
tively). A similar analysis in transformed lymphocytes
showed no eQTL24 enrichment (enrichment p ¼ 0.502).
T2D and Glucose-Trait-Associated SNPs: Distal and
Tissue-Specific Effects
These data suggested that GWAS SNPs have broad-reaching
and tissue-specific effects that often extend beyond and
may not generally include local transcripts. In adipose, 20
transcripts associated with established T2D/GT SNPs
were found to be differentially expressed between insulin-
resistant and insulin-sensitive individuals. In muscle, five
such transcripts were identified. All were trans associations
with replicated T2D/GT SNPs. No transcripts associated
with both T2D/GT SNPs and insulin sensitivity were shared
in adipose and muscle, supporting tissue specificity in
the transcriptional effects of disease-associated SNPs.
Furthermore, although no T2D/GT SNP was a cis-acting
eQTL for differentially expressed transcripts in both adi-
pose andmuscle, a T2D/GT SNP (rs2881654) was associated
with distal and differentially expressed transcripts in adi-
pose (PHF20L1, C13orf1, CRTAP [MIM 605497], and
REEP3 [MIM 609348]) and muscle (HDAC10 and GGT6),
supporting the broad-reaching and tissue specific effects
of disease-associated SNPs.
Cis and trans eQTLs in Additional Tissues
One possible explanation for our findings was the possi-
bility that nearly all associations described to date alter ex-
pression inan inaccessible tissue in a tissue-specificmanner.
To confirm the lack of cis eQTLs near T2D- and glucose-
homeostasis-associated SNPs, we examined liver for tran-
scripts associated with T2D/GT SNPs.16 From the 68
T2D/GT SNPs and the nearly 20,000 transcripts tested, we
identified a significant trans eQTL rs10787315 for INPP4B
(MIM 607494) (p ¼ 1.9 3 108). However, no transcript
was found to be cis associated with a T2D/GT SNP even at
the loose threshold p < 103. Hence, extended cis analysis
in liver confirmed the muscle and adipose findings that
although eQTLs are found among disease-associated SNPs,
they are most often not close to their target transcripts.
To gain further insight into the regulatory role of the
T2D/GT SNPs, we examined the recently published open
chromatin map in pancreatic islets33 for overlap with
the susceptibility variants. In particular, we sought to iden-
tify islet-selective open chromatin sites with islet-specific
effects on target transcripts. This open chromatin map
identified 340 genes with islet-selective open chromatin
in the TSS or gene body. Only four transcripts near
T2D/GT SNPs (namely, these transcripts are SLC30A8
[MIM 611145], ABCC8 [MIM 600509], FAM148A [MIM
610343], and G6PC2 [MIM 608058]) overlap this list; this
number is no more than what is expected by chance
(p ¼ 0.38, Fisher’s exact test).
We then analyzed the most detailed transcriptome map
of pancreatic b-cells to date34 from studies of humaner 7, 2012
Figure 2. Top T2D SNPs Are Enriched for
trans Regulatory Variation
For each tissue, quantile-quantile (Q-Q)
plots show, relative to expectation, an
excess of trans-regulatory variation and
a paucity of cis eQTLs among the top asso-
ciations with T2D in the Wellcome Trust
Case Control study. Adipose is shown on
the left; muscle is shown on the right.
Red (blue) indicates the distribution of
p values for all trans (cis, respectively) asso-
ciations with transcript levels for the top
associations with T2D. The x axis is the ex-
pected –log10(p value), and the y axis is
the observed –log10(p value).pancreatic islet samples and microarray analyses of puri-
fied rat beta cells, alpha cells, and INS-1 cells. This map
identified 940 genes specific to pancreatic islets, of which
324 are likely to be primarily expressed in b-cells.34 Inter-
estingly, only 11 of the 183 transcripts near T2D/GT
SNPs overlap this list, and this number is no more than
what is expected by chance (p ¼ 0.24, Fisher’s exact test).
Taken together, these findings from studies of pancreatic
islets support the paucity of cis eQTLs among T2D/GT
SNPs observed in other diabetes-relevant tissues.T2D- and Glucose-Homeostasis-Trait-Associated SNPs
Converge on Trans Genes that Are Associated with
Insulin Sensitivity
We sought to test the hypothesis that multiple replicated
T2D/GT SNPs, as putative trans eQTLs, converged on the
same downstream transcripts that were significantly asso-
ciated with insulin sensitivity (FDR < 0.05). We found
rs4607103 (on chromosome 3) and rs7754840 (on chro-
mosome 6) were both trans associated with GPAM, a gene
that is involved in triacylglycerol and phospholipid
synthesis and that was significantly associated with insulin
sensitivity in adipose in our data set. In adipose, the SNPs
rs1552224 (on chromosome 11) and rs1801282 (on chro-
mosome3)wereboth trans associatedwithPHF20L1,which
was a transcript differentially expressed between insulin-
sensitive and insulin-resistant individuals. We found the
SNPs rs13081389 (on chromosome 3) and rs243021 (on
chromosome 2) implicated the insulin-sensitivity-associ-
ated adipose transcript TTC7B.35The Observed eQTL Enrichment to Top GWAS Signals
Is Generalizable in Independent T2D GWASs
Because the number of well-replicated T2D and glucose-
homeostasis-associated SNPs evaluated above represented
a limited set, we asked more generally whether SNPs that
were ranked at the top for association with T2D but that
were not necessarily replicated were also enriched for
eQTLs from adipose andmuscle. Using theWellcome Trust
Case Control study,29 we tested whether the SNPs ranked
at the top for association with T2D (n ¼ 1,000) showedThe Americanan excess for trans eQTLs and, separately, for cis eQTLs.
As in the case of T2D/GT SNPs, neither trans eQTLs nor
cis eQTLs in transformed lymphocytes were highly en-
riched (enrichment p > 0.05) among the top associations
with T2D. In contrast, trans associations with transcripts
(as putative eQTLs) were enriched among the top associa-
tions in both adipose and muscle in comparison to expec-
tations. Consistent with our earlier findings on the 68
T2D/GT SNPs, cis eQTLs showed no enrichment among
the top associations. Figure 2 shows, for each tissue,
quantile-quantile (Q-Q) plots that demonstrate, relative
to expectation, an excess of trans-regulatory variation
and a paucity of cis eQTLs among the top associations
with T2D. Similarly, Figure S1 shows, for each tissue, the
Q-Q plots for the distributions of p values for the trans
and cis associations with transcripts differentially ex-
pressed between insulin-sensitive and insulin-resistant
individuals for the top SNP associations with T2D.
An analysis of a GWAS of T2D in Mexican Americans30
from Starr County, TX gave similar results. Among the
top associations (p < 103), we observed a significant
enrichment for trans associations with transcript levels in
adipose and muscle (enrichment p < 0.001 in each tissue).
Thus, we demonstrate (1) that unlike lymphocytes,
adipose and muscle can be used to identify likely func-
tional variants among the top GWAS associations; (2)
that our sample was adequate to show, over a range of
p values, eQTL enrichment that distinguished T2D suscep-
tibility variants from a random set of MAF-matched SNPs;
and (3) that only a minority of SNPs with replicated asso-
ciations with T2D and glucose-homeostasis traits act in
cis in the diabetes-relevant tissues examined here (adipose,
muscle, and liver) and that the number of cis eQTLs is
nearly exactly what is expected, whereas the number of
associations in trans is highly significantly increased rela-
tive to the null expectation.Discussion
Few variants with replicated associations with T2D, fasting
or postchallenge glucose levels, or insulin levels are codingJournal of Human Genetics 91, 466–477, September 7, 2012 473
or are known to be in strong linkage disequilibrium with
coding SNPs. This observation would suggest that most
SNPs act to alter gene expression and/or splicing rather
than tomodify gene products. Most published associations
of sequence variants with T2D and glucose-homeostasis
traits have identified transcripts in the general proximity
of the associated variant as likely to be responsible,
although for many of the regions tested in the current
study, multiple transcripts are in close proximity to the
most strongly associated SNP. With few exceptions, func-
tional data implicating specific transcripts are lacking.
Even for the widely expressed gene TCF7L2 near the
variant most strongly associated with T2D, rs7903146,
the functional consequences have been elusive until
recently.33
Several studies have recently shown the value of eQTL
mapping in surrogate tissues as a means of enhancing
discovery and defining the function of SNPs identified in
GWAS findings11,12,17. Similar results have been obtained
in tissues of physiological relevance.36 Another recently
published study37 showed that eQTLs in metabolically
relevant tissues were enriched for T2D associations.
However, the converse, that well-replicated SNPs associ-
ated with T2D or glucose homeostasis traits are enriched
for eQTLs or mark regions with eQTLs, has never been
comprehensively evaluated.
We investigated this question by using several ap-
proaches. First, we asked whether transcripts near these
SNPs were indeed controlled by any cis eQTL, given the
likelihood that the disease-associated SNP is not the func-
tional SNP and that stronger associations might exist
between other SNPs and nearby transcripts. Second, we
tested the confirmed T2D and glucose-homeostasis-associ-
ated SNPs for a direct effect on gene expression locally or
distally, particularly on transcripts differentially expressed
between insulin-sensitive and insulin-resistant individ-
uals. Third, to generalize our findings we extended our
analysis to the top signals from two independent large-
scale GWAS, evaluated separately. Whereas the set of
well-replicated SNPs for T2D and glucose homeostasis
traits tested the functional significance of our current
understanding of T2D susceptibility associations, the ex-
tended analysis of top T2D GWAS SNPs explored addi-
tional potential loci and suggested a means to prioritize
these loci using functional data. In both analyses, the level
and significance of the enrichment were tissue-specific,
with highly significant enrichment in adipose and muscle,
but not in lymphocytes.
Our study highlights the unanticipated importance of
T2D susceptibility loci as trans-acting regulators that often
act on multiple distal transcripts. Surprisingly, neither the
well-replicated T2D- and glucose-homeostasis-associated
loci nor the top 1,000 T2D-associated SNPs showed a signif-
icant enrichment of cis-acting regulation of target tran-
scripts in any of the four tissues examined: adipose,
muscle, lymphocytes, or liver. Although islet tissue was
not directly available for study, islet-specific open chro-474 The American Journal of Human Genetics 91, 466–477, Septembmatin regions33 mark potential regions with cis-acting
regulatory variants. We found that the number of genes
that have islet-selective open chromatin in the TSS or
gene body and overlap the regions near T2D/GT SNPs is
not greater than expected by chance, thus indirectly sup-
porting our hypothesis that most T2D and glucose-homeo-
stasis susceptibility loci mediate their effects in a broad
array of diabetes-relevant tissues through the regulation
of distal transcripts.
Our study extends previous studies on the use of func-
tional genomic data to enrich information provided in
GWASs. Perry et al.38 sought to use gene-set enrichment
to identify pathways enriched in T2D-associated SNPs,
but they failed to identify any single pathways enriched
for replicated SNPs. They did not directly test these SNPs
for function. Parikh et al.39 examined expression profiling
in public data sets from pancreas, adipose tissue, liver, and
skeletal muscle from T2D and control tissues taken from
a variety of relatively small studies of humans, rats, and
mice. They selected 1,170 SNPs associated with T2D at
p < 0.05. This corresponded to 243 genes, of which they
reported that 115 were differentially expressed between
diabetic and healthy tissues in any sample. Consistent
with our observation on the absence of cis control of tran-
scripts near replicated T2D-associated SNPs, only 5/115
differentially expressed genes had nearby T2D-associated
SNPs. Zhong et al.36 recently used eQTLs in metabolically
relevant tissues along with gene-set enrichment to search
for nonreplicated SNPs that both control gene expression
and cluster in pathways. Although their approach was to
use function and association to identify important geneti-
cally controlled pathways, among their positive controls
were 18 genes near replicated T2D GWAS SNPs. Their
finding showed that cis eQTLs controlled transcripts
NOTCH2 (MIM 600275), ADAMTS9 (MIM 605421),
JAZF1, TSPAN8 (MIM 600769), PPARG (MIM 601487),
and CDKAL1, and thus partially overlaps with the findings
from our transcript-based analysis. Differences might re-
flect sample ascertainment, sample size, and tissues chosen
for analysis. Interestingly, a second recent study from these
investigators37 focused on cis-acting variants for tran-
scripts in a B6xBTBR mouse cross and human genome-
wide gene-expression cohorts. Of the 159 expression traits
in the adipose ‘‘causal’’ subnetwork, 117 gave rise to an
eQTL in a distinct region of chromosome 9, but only eight
of these adipose transcripts were associated with a cis
eQTL. These findings in a subnetwork selected from
mouse crosses support our findings in human samples
for transcripts near GWAS SNPs: Transcripts associated
with glucose homeostasis are with some exceptions not
under local control.
It is certainly possible that all of the results we have
observed in muscle, adipose, and liver tissue are down-
stream of functional effects of these SNPs on nearby tran-
scripts in pancreatic b-cells. Similarly, the fact that more
of the transcripts implicated through trans associations
with T2D/GT SNPs were differentially expressed in muscleer 7, 2012
and/or adipose could relate to the possibility that insulin
sensitivity is a consequence of these downstream effects
of SNPs that act in cis on nearby transcripts in b-cells. We
would argue, however, that the biological insights related
to the gene transcripts that have been implicated in these
studies are no less important even if that were to be true.
Transcripts that are implicated through multiple of the
T2D/GT SNPs within and/or across tissues and that are
also differentially expressed in insulin-sensitive versus
insulin-resistant subjects are of great biological interest
whether they are directly implicated in trans fashion in
muscle and adipose tissues or are implicated through
downstream effects of other transcripts targeted in cis by
T2D/GT SNPs in b-cells. These findings illustrate well the
value of using -omics tools to uncover biology relevant to
complex phenotypes such as those involving T2D and
glucose homeostasis; given how much we have to learn
about how genetic risk factors actually alter risk for T2D,
that value is hardly diminished if the effects are somewhat
downstream of primary effects that we have not yet
appreciated.
Although, as noted above, we recognize that the effects
we observe may not be the primary way that T2D/GT
SNPs alter risk of T2D, our results nevertheless suggest
that we be cautious about making assumptions regarding
the functional role of SNPs identified in GWASs as cis regu-
lators of expression, and they raise the possibility that, at
least for T2D and glucose homeostasis, many well-repli-
cated SNPs may act, by unclear mechanisms, distally on
the same chromosome or on different chromosomes.
These findings have obvious implications for the design
of follow-up studies for GWASs, which to date have largely
focused on sequencing of local regions. Clearly, transcripts
predicted by multiple independent associated SNPs are
strong candidates for inclusion in such sequencing studies.
These studies also raise the question of whether patterns of
cis or trans transcript regulation are a key feature of the
architecture of complex traits. Studies similar to these in
other tissues, in larger samples, and for other diseases
will be critical to answering this question and may be
useful for understanding the genetic architecture of com-
plex disease.Supplemental Data
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